A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints

Interference of the binding of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) has become a new inspiring immunotherapy for resisting cancers. To date, the FDA has approved two PD-1 monoclonal antibody drugs against cancer as well as a monoclonal antibody for PD-L1. More...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yongshu, Li, Fangfei, Jiang, Feng, Lv, Xiaoqing, Zhang, Rongjiang, Lu, Aiping, Zhang, Ge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964524/
https://www.ncbi.nlm.nih.gov/pubmed/27438833
http://dx.doi.org/10.3390/ijms17071151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964524/
https://www.ncbi.nlm.nih.gov/pubmed/27438833
http://dx.doi.org/10.3390/ijms17071151

Ejemplares similares